Xuanzhu Biopharm-B (02575): Data from Phase III Clinical Study of Anlanzole Sodium in Treating Reflux Esophagitis Presented at UEG Week 2026

Zhitong Finance APP News, Xuanzhu Biopharma-B (02575) announced that the results of the Phase III registrational clinical study of Anelazole Sodium Enteric-Coated Tablets, a Class 1 innovative drug independently developed by the Group, for the treatment of reflux esophagitis were recently presented in an oral presentation as a Late-Breaking Abstract (LB25) at the 34th United European Gastroenterology Week (UEG Week 2026) held in Barcelona, Spain.